Developing potent LC3-targeting AUTAC tools for protein degradation with selective autophagy

Junping Pei,Xiaoli Pan,Aoxue Wang,Wen Shuai,Faqian Bu,Pan Tang,Shuai Zhang,Yiwen Zhang,Guan Wang,Liang Ouyang

DOI: https://doi.org/10.1039/d1cc04661f

IF: 4.9

2021-01-01

Chemical Communications

Abstract:Autophagy-based protein degradation is emerging as a promising technology for anti-diseases and innovative drug discovery.

chemistry, multidisciplinary

What problem does this paper attempt to address?

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Shanshan Gu,Di Cui,Xiaoyu Chen,Xiufang Xiong,Yongchao Zhao

DOI: https://doi.org/10.1002/bies.201700247

2018-01-01

BioEssays

Abstract:Proteolysis-targeting chimeric molecules (PROTACs) represent an emerging technique that is receiving much attention for therapeutic intervention. The mechanism is based on the inhibition of protein function by hijacking a ubiquitin E3 ligase for protein degradation. The hetero-bifunctional PROTACs contain a ligand for recruiting an E3 ligase, a linker, and another ligand to bind with the protein targeted for degradation. Thus, PROTACs have profound potential to eliminate "undruggable" protein targets, such as transcription factors and non-enzymatic proteins, which are not limited to physiological substrates of the ubiquitin-proteasome system. These findings indicate great prospects for PROTACs in the development of therapeutics. However, there are several limitations related to poor stability, biodistribution, and penetrability in vivo. This review provides an overview of the main PROTAC-based approaches that have been developed and discusses the promising opportunities and considerations for the application of this technology in therapies and drug discovery.
Inhibition of Autophagy by a Small Molecule Through Covalent Modification of the LC3 Protein

Shijie Fan,Liyan Yue,Wei Wan,Yuanyuan Zhang,Bidong Zhang,Chinatsu Otomo,Quanfu Li,Tingting Lin,Junchi Hu,Pan Xu,Mingrui Zhu,Hongru Tao,Zhifeng Chen,Lianchun Li,Hong Ding,Zhiyi Yao,Junyan Lu,Yi Wen,Naixia Zhang,Minjia Tan,Kaixian Chen,Yuli Xie,Takanori Otomo,Bing Zhou,Hualiang Jiang,Yongjun Dang,Cheng Luo

DOI: https://doi.org/10.1002/anie.202109464

2021-01-01

Angewandte Chemie

Abstract:The autophagic ubiquitin-like protein LC3 functions through interactions with LC3-interaction regions (LIRs) of other autophagy proteins, including autophagy receptors, which stands out as a promising protein-protein interaction (PPI) target for the intervention of autophagy. Post-translational modifications like acetylation of Lys49 on the LIR-interacting surface could disrupt the interaction, offering an opportunity to design covalent small molecules interfering with the interface. Through screening covalent compounds, we discovered a small molecule modulator of LC3A/B that covalently modifies LC3A/B protein at Lys49. Activity-based protein profiling (ABPP) based evaluations reveal that a derivative molecule DC-LC3in-D5 exhibits a potent covalent reactivity and selectivity to LC3A/B in HeLa cells. DC-LC3in-D5 compromises LC3B lipidation in vitro and in HeLa cells, leading to deficiency in the formation of autophagic structures and autophagic substrate degradation. DC-LC3in-D5 could serve as a powerful tool for autophagy research as well as for therapeutic interventions.
Autophagy mediated targeting degradation, a promising strategy in drug development

Jiantao Zhang,Xiangyi Pan,Wenshu Ji,Jinming Zhou

DOI: https://doi.org/10.1016/j.bioorg.2024.107466

Abstract:Targeted protein degradation (TPD) technologies have become promising therapeutic approaches through degrading disease-causing proteins via the protein degradation system. Autophagy is a fundamental biological process with a high relationship to protein degradation, which belongs to one of two main protein degradation pathways, the autophagy-lysosomal system. Recently, various autophagy-based TPD techniques ATTECs, AUTACs, and AUTOTACs, etc, have also been gradually developed, and they have achieved efficient degradation potency for the targeted protein, expanding the potential of degradation for large-size proteins or protein aggregates. Herein, we introduce the machinery of autophagy and its relation to protein degradation, and multiple methods for using autophagy to specifically degrade target proteins.
The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system

Chang Hoon Ji,Hee Yeon Kim,Min Ju Lee,Ah Jung Heo,Daniel Youngjae Park,Sungsu Lim,Seulgi Shin,Srinivasrao Ganipisetti,Woo Seung Yang,Chang An Jung,Kun Young Kim,Eun Hye Jeong,Sun Ho Park,Su Bin Kim,Su Jin Lee,Jeong Eun Na,Ji In Kang,Hyung Min Chi,Hyun Tae Kim,Yun Kyung Kim,Bo Yeon Kim,Yong Tae Kwon

DOI: https://doi.org/10.1038/s41467-022-28520-4

IF: 16.6

2022-02-16

Nature Communications

Abstract:Abstract Targeted protein degradation allows targeting undruggable proteins for therapeutic applications as well as eliminating proteins of interest for research purposes. While several degraders that harness the proteasome or the lysosome have been developed, a technology that simultaneously degrades targets and accelerates cellular autophagic flux is still missing. In this study, we develop a general chemical tool and platform technology termed AUTOphagy-TArgeting Chimera (AUTOTAC), which employs bifunctional molecules composed of target-binding ligands linked to autophagy-targeting ligands. AUTOTACs bind the ZZ domain of the otherwise dormant autophagy receptor p62/Sequestosome-1/SQSTM1, which is activated into oligomeric bodies in complex with targets for their sequestration and degradation. We use AUTOTACs to degrade various oncoproteins and degradation-resistant aggregates in neurodegeneration at nanomolar DC 50 values in vitro and in vivo. AUTOTAC provides a platform for selective proteolysis in basic research and drug development.

multidisciplinary sciences
Manipulating Autophagic Degradation in Human Diseases: from Mechanisms to Interventions

Yiqing Zhang,Xiaoxia Liu,Daniel J Klionsky,Boxun Lu,Qing Zhong

DOI: https://doi.org/10.1093/lifemedi/lnac043

2022-01-01

Abstract:Targeted degradation, having emerged as a powerful and promising strategy in drug discovery in the past two decades, has provided a solution for many once undruggable targets involved in various diseases. While earlier targeted degradation tools, as exemplified by PROteolysis-TArgeting Chimera (PROTAC), focused on harnessing the ubiquitin-proteasome system, novel approaches that aim to utilize autophagy, a potent, lysosome-dependent degradation pathway, have also surfaced recently as promising modalities. In this review, we first introduce the mechanisms that establish selectivity in autophagy, which provides the rationales for autophagy-based targeted degradation; we also provide an overview on the panoply of cellular machinery involved in this process, an arsenal that could be potentially harnessed. On this basis, we propose four strategies for designing autophagy-based targeted degraders, including Tagging Targets, Directly Engaging Targets, Initiating Autophagy at Targets, and Phagophore-Tethering to Targets. We introduce the current frontiers in this field, including AUtophagy-TArgeting Chimera (AUTAC), Targeted Protein Autophagy (TPA), AUTOphagy-TArgeting Chimera (AUTOTAC, not to be confused with AUTAC), AuTophagosome TEthering Compound (ATTEC), and other experimental approaches as case studies for each strategy. Finally, we put forward a workflow for generating autophagy-based degraders and some important questions that may guide and inspire the process.
Emerging degrader technologies engaging lysosomal pathways

Yu Ding,Dong Xing,Yiyan Fei,Boxun Lu

DOI: https://doi.org/10.1039/d2cs00624c

2022-10-31

Abstract:Targeted protein degradation (TPD) provides unprecedented opportunities for drug discovery. While the proteolysis-targeting chimera (PROTAC) technology has already entered clinical trials and changed the landscape of small-molecule drugs, new degrader technologies harnessing alternative degradation machineries, especially lysosomal pathways, have emerged and broadened the spectrum of degradable targets. We have recently proposed the concept of autophagy-tethering compounds (ATTECs) that hijack the autophagy protein microtubule-associated protein 1A/1B light chain 3 (LC3) for targeted degradation. Other groups also reported degrader technologies engaging lysosomal pathways through different mechanisms including AUTACs, AUTOTACs, LYTACs and MoDE-As. In this review, we analyse and discuss ATTECs along with other lysosomal-relevant degrader technologies. Finally, we will briefly summarize the current status of these degrader technologies and envision possible future studies.
Perspectives of Autophagy-Tethering Compounds (attecs) in Drug Discovery

Yu Ding,Dong Xing,Yiyan Fei,Shouqing Luo,Boxun Lu

DOI: https://doi.org/10.1016/j.medp.2023.100004

2024-01-01

Abstract:Degrader technologies provide unprecedented strategies to tackle diseases caused by pathogenic proteins that are difficult to target by the traditional inhibitor approach. One pioneering technology, proteolysis-targeting chimera (PROTAC), has revolutionized small-molecule drug discovery. However, PROTACs hijack the ubiquitination-proteasome pathway, which is incapable of degrading certain categories of targets. To address this limitation, scientists introduced autophagy-tethering compounds (ATTECs), capitalizing on the autophagosome protein LC3 to selectively break down both pathogenic proteins and organelles. This review explores multiple dimensions of ATTECs, focusing on their mechanisms of action and potential applications in drug discovery.
Drug discovery by targeting the protein‒protein interactions involved in autophagy

Honggang Xiang,Mi Zhou,Yan Li,Lu Zhou,Renxiao Wang

DOI: https://doi.org/10.1016/j.apsb.2023.07.016

IF: 14.903

2023-07-22

Acta Pharmaceutica Sinica B

Abstract:Autophagy is a cellular process in which proteins and organelles are engulfed in autophagosomal vesicles and transported to the lysosome/vacuole for degradation. Protein‒protein interactions (PPIs) play a crucial role at many stages of autophagy, which present formidable but attainable targets for autophagy regulation. Moreover, selective regulation of PPIs tends to have a lower risk in causing undesired off-target effects in the context of a complicated biological network. Thus, small-molecule regulators, including peptides and peptidomimetics, targeting the critical PPIs involved in autophagy provide a new opportunity for innovative drug discovery. This article provides general background knowledge of the critical PPIs involved in autophagy and reviews a range of successful attempts on discovering regulators targeting those PPIs. Successful strategies and existing limitations in this field are also discussed.

pharmacology & pharmacy
Targeting Lysosomal Degradation Pathways: New Strategies and Techniques for Drug Discovery

Junping Pei,Guan Wang,Lu Feng,Jifa Zhang,Tingting Jiang,Qiu Sun,Liang Ouyang

DOI: https://doi.org/10.1021/acs.jmedchem.0c01689

2021-04-08

Abstract:A series of tools for targeted protein degradation are inspiring scientists to develop new drugs with advantages over traditional small-molecule drugs. Among these tools, proteolysis-targeting chimeras (PROTACs) are most representative of the technology based on proteasomes. However, the proteasome has little degradation effect on certain macromolecular proteins or aggregates, extracellular proteins, and organelles, which limits the application of PROTACs. Additionally, lysosomes play an important role in protein degradation. Therefore, lysosome-induced protein degradation drugs can directly regulate protein levels in vivo, achieve the goal of treating diseases, and provide new strategies for drug discovery. Lysosome-based degradation technology has the potential for clinical translation. In this review, strategies targeting lysosomal pathways and lysosome-based degradation techniques are summarized. In addition, lysosome-based degrading drugs are described, and the advantages and challenges are listed. Our efforts will certainly promote the design, discovery, and clinical application of drugs associated with this technology.
Targeting Lipid Droplets for Autophagic Degradation by ATTEC

Yuhua Fu,Boxun Lu

DOI: https://doi.org/10.1080/15548627.2021.1967616

IF: 13.391

2021-01-01

Autophagy

Abstract:Targeted protein degradation (TPD) provides unprecedented drug discovery strategies, but it is incapable of degrading non-protein pathogenic biomolecules. We have previously developed the concept of autophagosome-targeting compounds (ATTEC), which can target pathogenic proteins to autophagic degradation. Since macroautophagy (autophagy hereafter) is capable of degrading a wide spectrum of substrates including non-protein biomolecules, ATTEC should also be capable of targeting those non-protein biomolecules for autophagic degradation. Here in our most recent study, we have demonstrated this possibility using lipid droplets (LDs) as an exemplar target. LDs are intracellular structures storing neutral lipids, which can be degraded by autophagy. Based on the concept of ATTEC, compounds binding with both the LDs and the key phagophore and autophagosome protein LC3 may target LDs to autophagic degradation. We designed and synthesized such compounds by connecting the identified LC3-binding molecules to known LD-binding probes via a chemical linker. At micromolar concentrations, these compounds drastically reduced LDs via autophagy through the predicted mechanism, and rescued LD-related phenotypes in cells and in two independent mouse models with hepatic lipidosis. Our proof-of-concept study demonstrates the possibility of harnessing autophagy to degrade non-protein biomolecules by ATTEC.
Discovery of small molecules for autophagy-lysosome degradation of immune checkpoint proteins

Kaizhen Wang,Zhihao Qi,Jiazheng Guo,Guoqing Shen,Xiang Ni,Sheng Jiang,Kuojun Zhang,Tianyu Wang,Xiangyu Zhang

DOI: https://doi.org/10.1016/j.ejmech.2024.116958

2024-12-15

Abstract:Targeted protein degradation (TPD) technologies, particularly proteolysis targeting chimeras (PROTACs), have emerged as a promising branch of targeted therapy. Current ubiquitin-proteasome-dependent TPD technologies are limited to targeting intracellular proteins. Although the blockade of immune checkpoints has achieved great clinical success, most immune checkpoints are transmembrane proteins, which are difficult to be ubiquitinated and degraded by PROTACs. Herein, we developed a novel discovery strategy of bifunctional small molecules, which could mediate autophagy-lysosome degradation of immune checkpoints. F-1 was demonstrated to activate the autophagy-lysosome system, and conjugation of F-1 with inhibitors targeting programmed cell death-ligand 1 (PD-L1) or V-domain Ig suppressor of T-cell activation (VISTA) generated a new class of small molecules that effectively induce the degradation of PD-L1 or VISTA in tumor cells. The most promising PD-L1 degrader B3 significantly induced PD-L1 degradation in RKO cells through the autophagy-lysosome system and exhibited good tumor-inhibiting effects in vivo. Our work could expand the development of degraders targeting immune checkpoints and provide a promising discovery strategy for future autophagy-lysosome targeting degradation technology.
Degradation of Lipid Droplets by Chimeric Autophagy-Tethering Compounds

Yuhua Fu,Ningxie Chen,Ziying Wang,Shouqing Luo,Yu Ding,Boxun Lu

DOI: https://doi.org/10.1038/s41422-021-00532-7

2021-01-01

Abstract:Degrading pathogenic proteins by degrader technologies such as PROTACs (proteolysis-targeting chimeras) provides promising therapeutic strategies, but selective degradation of non-protein pathogenic biomolecules has been challenging. Here, we demonstrate a novel strategy to degrade non-protein biomolecules by autophagy-tethering compounds (ATTECs), using lipid droplets (LDs) as an exemplar target. LDs are ubiquitous cellular structures storing lipids and could be degraded by autophagy. We hypothesized that compounds interacting with both the LDs and the key autophagosome protein LC3 may enhance autophagic degradation of LDs. We designed and synthesized such compounds by connecting LC3-binding molecules to LD-binding probes via a linker. These compounds were capable of clearing LDs almost completely and rescued LD-related phenotypes in cells and in two independent mouse models with hepatic lipidosis. We further confirmed that the mechanism of action of these compounds was mediated through LC3 and autophagic degradation. Our proof-of-concept study demonstrates the capability of degrading LDs by ATTECs. Conceptually, this strategy could be applied to other protein and non-protein targets.
Targeting autophagy in disease: established and new strategies

Muhammed Kocak,Saba Ezazi Erdi,Guillem Jorba,Inés Maestro,Judith Farrés,Vladimir Kirkin,Ana Martinez,Ole Pless

DOI: https://doi.org/10.1080/15548627.2021.1936359

IF: 13.391

2021-07-09

Autophagy

Abstract:Macroautophagy/autophagy is an evolutionarily conserved pathway responsible for clearing cytosolic aggregated proteins, damaged organelles or invading microorganisms. Dysfunctional autophagy leads to pathological accumulation of the cargo, which has been linked to a range of human diseases, including neurodegenerative diseases, infectious and autoimmune diseases and various forms of cancer. Cumulative work in animal models, application of genetic tools and pharmacologically active compounds, has suggested the potential therapeutic value of autophagy modulation in disease, as diverse as Huntington, Salmonella infection, or pancreatic cancer. Autophagy activation versus inhibition strategies are being explored, while the role of autophagy in pathophysiology is being studied in parallel. However, the progress of preclinical and clinical development of autophagy modulators has been greatly hampered by the paucity of selective pharmacological agents and biomarkers to dissect their precise impact on various forms of autophagy and cellular responses. Here, we summarize established and new strategies in autophagy-related drug discovery and indicate a path toward establishing a more efficient discovery of autophagy-selective pharmacological agents. With this knowledge at hand, modern concepts for therapeutic exploitation of autophagy might become more plausible.Abbreviations: ALS: amyotrophic lateral sclerosis; AMPK: AMP-activated protein kinase; ATG: autophagy-related gene; AUTAC: autophagy-targeting chimera; CNS: central nervous system; CQ: chloroquine; GABARAP: gamma-aminobutyric acid type A receptor-associated protein; HCQ: hydroxychloroquine; LYTAC: lysosome targeting chimera; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MTOR: mechanistic target of rapamycin kinase; NDD: neurodegenerative disease; PDAC: pancreatic ductal adenocarcinoma; PE: phosphatidylethanolamine; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PtdIns3K: class III phosphatidylinositol 3-kinase; PtdIns3P: phosphatidylinositol 3-phosphate; PROTAC: proteolysis-targeting chimera; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; SQSTM1/p62: sequestosome 1; ULK1: unc-51 like autophagy activating kinase 1.
Tethering ATG16L1 or LC3 induces targeted autophagic degradation of protein aggregates and mitochondria

Ligang Mei,Xiaorong Chen,Fujing Wei,Xue Huang,Lu Liu,Jia Yao,Jing Chen,Xunguang Luo,Zhuolin Wang,Aimin Yang

DOI: https://doi.org/10.1080/15548627.2023.2234797

IF: 13.391

2023-07-15

Autophagy

Abstract:Proteolysis-targeting chimeras (PROTACs) based on the ubiquitin-proteasome system have made great progress in the field of drug discovery. There is mounting evidence that the accumulation of aggregation-prone proteins or malfunctioning organelles is associated with the occurrence of various age-related neurodegenerative disorders and cancers. However, PROTACs are inefficient for the degradation of such large targets due to the narrow entrance channel of the proteasome. Macroautophagy (hereafter referred to as autophagy) is known as a self-degradative process involved in the degradation of bulk cytoplasmic components or specific cargoes that are sequestered into autophagosomes. In the present study, we report the development of a generalizable strategy for the targeted degradation of large targets. Our results suggested that tethering large target models to phagophore-associated ATG16L1 or LC3 induced targeted autophagic degradation of the large target models. Furthermore, we successfully applied this autophagy-targeting degradation strategy to the targeted degradation of HTT65Q aggregates and mitochondria. Specifically, chimeras consisting of polyQ-binding peptide 1 (QBP) and ATG16L1-binding peptide (ABP) or LC3-interacting region (LIR) induced targeted autophagic degradation of pathogenic HTT65Q aggregates; and the chimeras consisting of mitochondria-targeting sequence (MTS) and ABP or LIR promoted targeted autophagic degradation of dysfunctional mitochondria, hence ameliorating mitochondrial dysfunction in a Parkinson disease cell model and protecting cells from apoptosis induced by the mitochondrial stress agent FCCP. Therefore, this study provides a new strategy for the selective proteolysis of large targets and enrich the toolkit for autophagy-targeting degradation. Abbreviations: ABP: ATG16L1-binding peptide; ATG16L1: autophagy related 16 like 1; ATTEC: autophagy-tethering compound; AUTAC: autophagy-targeting chimera; AUTOTAC: autophagy-targeting chimera; Baf A1: bafilomycin A 1 ; BCL2: BCL2 apoptosis regulator; CALCOCO2/NDP52: calcium binding and coiled-coil domain 2; CASP3: caspase 3; CPP: cell-penetrating peptide; CQ: chloroquine phosphate; DAPI: 4',6-diamidino-2-phenylindole; DCM: dichloromethane; DMF: N,N-dimethylformamide; DMSO: dimethyl sulfoxide; EBSS: Earle′s balanced salt solution; FCCP: carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone; FITC: fluorescein-5-isothiocyanate; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GFP: green fluorescent protein; HEK293: human embryonic kidney 293; HEK293T: human embryonic kidney 293T; HPLC: high-performance liquid chromatography; HRP: horseradish peroxidase; HTT: huntingtin; LIR: LC3-interacting region; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MFF: mitochondrial fission factor; MTS: mitochondria-targeting sequence; NBR1: NBR1 autophagy cargo receptor; NLRX1: NLR family member X1; OPTN: optineurin; P2A: self-cleaving 2A peptide; PB1: Phox and Bem1p; PBS: phosphate-buffered saline; PE: phosphatidylethanolamine; PINK1: PTEN induced kinase 1; PRKN: parkin RBR E3 ubiquitin protein ligase; PROTACs: proteolysis-targeting chimeras; QBP: polyQ-binding peptide 1; SBP: streptavidin-binding peptide; SDS-PAGE: sodium dodecyl sulfate-polyacrylamide gel electrophoresis; SPATA33: spermatogenesis associated 33; TIMM23: translocase of inner mitochondrial membrane 23; TMEM59: transmembrane protein 59; TOMM20: translocase of outer mitochondrial membrane 20; UBA: ubiquitin-associated; WT: wild type.

cell biology
Advancing targeted protein degradation for metabolic diseases therapy

Qian-Qian Zhou,Hai-Tao Xiao,Fan Yang,Yong-Dan Wang,Ping Li,Zu-Guo Zheng

DOI: https://doi.org/10.1016/j.phrs.2022.106627

Abstract:The development and application of traditional drugs represented by small molecule chemical drugs and biological agents, especially inhibitors, have become the mainstream drug development. In recent years, targeted protein degradation (TPD) technology has become one of the most promising methods to remove specific disease-related proteins using cell self-destruction mechanisms. Many different TPD strategies are emerging based on the ubiquitin-proteasome system (UPS) and the autophagy-lysosomal pathway (ALP), including but not limited to proteolysis-targeting chimeras (PROTAC), molecular glues (MG), lysosome targeting chimeras (LYTAC), chaperone-mediated autophagy (CMA)-targeting chimeras, autophagy-targeting chimera (AUTAC), autophagosome-tethering compound (ATTEC), and autophagy-targeting chimera (AUTOTAC). The advent of targeted degradation technology can change most protein targets in human cells from undruggable to druggable, greatly expanding the therapeutic prospect of refractory diseases such as metabolic syndrome. Here, we summarize the latest progress of major TPD technologies, especially in metabolic syndrome and look forward to providing new insights for drug discovery.
Identification and Functional Studies of New Autoph-agy Protein Machinary

Yang Chen,Yule Liu,Hong Zhang,Wei Liu,Qiming Sun,Chonglin Yang,Zhihua Liu,Yiguo Wang,Li Yu

DOI: https://doi.org/10.3969/j.issn.1009-2412.2018.01.002

2018-01-01

Abstract:Autophagy is an evolutionally conserved lysosome ( vacuole)-dependent process, which degrades damaged or unwanted redundant cellular contents to generate bio-molecules. The function of autophagy has been shown to be tightly related to human health and diseases. The Nobel Prize in Physiology or Medicine 2016 was awar-ded to Yoshinori Ohsumi " for his discoveries of mecha-nisms for autophagy " . Current research on autophagy focus on Saccharomyces cerevisiae or essential protein machinaries identified from yeast genetic screenings. However, studies using single cell organisium yeast, or single induction conditions for autophagy have obvious limitations. In this review, we will propose several im-portant questions in the autophagy field. Multicellular organisms have differnet cells, tissue or developmental stages which certanly require new autophagy machinar-ies. This is an important directions for autophagy stud-ies, especially disease related studies. We should also pay more attention to the assembling mechanisums, the formation of protein complexes and posttranslational modifications of core machinary of autophagy. How the late stage of autophagy is regulated and the mechanism of lysosome biogenesis remains to be answered. Autoph-agy induced by multiple stimuli, for example energy de-pletion, is more related to physiology conditions and is the future directions of autophagy research. We will also discuss the strategies and technique development of au-tophagy studies.
Structure-Based Design and Discovery of a Potent and Cell-Active LC3A/B Covalent Inhibitor.

Zhenfei Zhou,Siqi Huang,Shijie Fan,Xueyuan Li,Chengyu Wang,Wanlin Yu,Daohai Du,Yuanyuan Zhang,Kaixian Chen,Wei Fu,Cheng Luo

DOI: https://doi.org/10.1021/acs.jmedchem.4c00898

IF: 8.039

2024-01-01

Journal of Medicinal Chemistry

Abstract:Autophagy is a highly conserved cellular homeostasis maintenance mechanism in eukaryotes. Microtubule-associated protein light chain 3 (LC3) plays a crucial role in autophagy. It has multiple pairs of protein-protein interactions (PPIs) with other proteins, and these PPIs have an effect on the regulation of autophagosome formation and the recruitment of autophagic substrates. In our previous work, a small molecule covalent inhibitor DC-LC3in-D5 which could inhibit LC3A/B PPIs was identified, but a detailed study of structure-activity relationships (SARs) was lacking. Herein, a new molecule LC3in-C42 was discovered utilizing the hybridization of advantageous fragments, whose potency (IC50 = 7.6 nM) had been greatly improved compared with that of DC-LC3in-D5. LC3in-C42 inhibits autophagy at the cellular level and its efficacy far exceeds that of DC-LC3in-D5. Thus far, LC3in-C42 stands as the most potent LC3A/B small molecule inhibitor. LC3in-C42 could serve as a powerful tool for LC3A/B protein and autophagy research.
Targeting autophagy drug discovery: Targets, indications and development trends

Mengjia Jiang,Wayne Wu,Zijie Xiong,Xiaoping Yu,Zihong Ye,Zhiping Wu

DOI: https://doi.org/10.1016/j.ejmech.2023.116117

IF: 7.088

2024-01-27

European Journal of Medicinal Chemistry

Abstract:Autophagy plays a vital role in sustaining cellular homeostasis and its alterations have been implicated in the etiology of many diseases. Drugs development targeting autophagy began decades ago and hundreds of agents were developed, some of which are licensed for the clinical usage. However, no existing intervention specifically aimed at modulating autophagy is available. The obstacles that prevent drug developments come from the complexity of the actual impact of autophagy regulators in disease scenarios. With the development and application of new technologies, several promising categories of compounds for autophagy-based therapy have emerged in recent years. In this paper, the autophagy-targeted drugs based on their targets at various hierarchical sites of the autophagic signaling network, e.g., the upstream and downstream of the autophagosome and the autophagic components with enzyme activities are reviewed and analyzed respectively, with special attention paid to those at preclinical or clinical trials. The drugs tailored to specific autophagy alone and combination with drugs/adjuvant therapies widely used in clinical for various diseases treatments are also emphasized. The emerging drug design and development targeting selective autophagy receptors (SARs) and their related proteins, which would be expected to arrest or reverse the progression of disease in various cancers, inflammation, neurodegeneration, and metabolic disorders, are critically reviewed. And the challenges and perspective in clinically developing autophagy-targeted drugs and possible combinations with other medicine are considered in the review.

chemistry, medicinal
Targeting the Undruggables ---- the Power of Protein Degraders

Chao Zhang,Yongbo Liu,Guangchen Li,Zhouli Yang,Chi Han,Xiuyun Sun,Chunquan Sheng,Ke Ding,Yu Rao

DOI: https://doi.org/10.1016/j.scib.2024.03.056

IF: 18.9

2024-01-01

Science Bulletin

Abstract:Undruggable targets typically refer to a class of therapeutic targets that are difficult to target through conventional methods or have not yet been targeted, but are of great clinical significance. According to statistics, over 80% of disease-related pathogenic proteins cannot be targeted by current conventional treatment methods. In recent years, with the advancement of basic research and new technologies, the development of various new technologies and mechanisms has brought new perspectives to overcome challenging drug targets. Among them, targeted protein degradation technology is a breakthrough drug development strategy for challenging drug targets. This technology can specifically identify target proteins and directly degrade pathogenic target proteins by utilizing the inherent protein degradation pathways within cells. This new form of drug development includes various types such as proteolysis targeting chimera (PROTAC), molecular glue, lysosome-targeting Chimaera (LYTAC), autophagosome-tethering compound (ATTEC), autophagy-targeting chimera (AUTAC), autophagy-targeting chimera (AUTOTAC), degrader-antibody conjugate (DAC). This article systematically summarizes the application of targeted protein degradation technology in the development of degraders for challenging drug targets. Finally, the article looks forward to the future development direction and application prospects of targeted protein degradation technology.
Targeted proteomics addresses selectivity and complexity of protein degradation by autophagy

Alexandre Leytens,Rocío Benítez-Fernández,Carlos Jiménez-García,Carole Roubaty,Michael Stumpe,Patricia Boya,Jörn Dengjel

DOI: https://doi.org/10.1080/15548627.2024.2396792

IF: 13.391

2024-09-22

Autophagy

Abstract:Macroautophagy/autophagy is a constitutively active catabolic lysosomal degradation pathway, often found dysregulated in human diseases. It is often considered to act in a cytoprotective manner and is commonly upregulated in cells undergoing stress. Its initiation is regulated at the protein level and does not require de novo protein synthesis. Historically, autophagy has been regarded as nonselective; however, it is now clear that different stimuli can lead to the selective degradation of cellular components via selective autophagy receptors (SARs). Due to its selective nature and the existence of multiple degradation pathways potentially acting in concert, monitoring of autophagy flux, i.e . selective autophagy-dependent protein degradation, should address this complexity. Here, we introduce a targeted proteomics approach monitoring abundance changes of 37 autophagy-related proteins covering process-relevant proteins such as the initiation complex and the Atg8-family protein lipidation machinery, as well as most known SARs. We show that proteins involved in autophagosome biogenesis are upregulated and spared from degradation under autophagy-inducing conditions in contrast to SARs, in a cell-line dependent manner. Classical bulk stimuli such as nutrient starvation mainly induce degradation of ubiquitin-dependent soluble SARs and not of ubiquitin-independent, membrane-bound SARs. In contrast, treatment with the iron chelator deferiprone leads to the degradation of ubiquitin-dependent and -independent SARs linked to mitophagy and reticulophagy/ER-phagy. Our approach is automatable and supports large-scale screening assays paving the way to (pre)clinical applications and monitoring of specific autophagy flux. Abbreviation: AMBRA1: autophagy and beclin 1 regulator 1; ATG: autophagy related; BafA1: bafilomycin A 1 ; BNIP1: BCL2 interacting protein 1; BNIP3: BCL2 interacting protein 3; BNIP3L/NIX: BCL2 interacting protein 3-like; CALCOCO2/NDP52: calcium binding and coiled-coil domain 2; CCPG1: cell cycle progression 1; CV: coefficients of variations; CCCP: carbonyl cyanide m-chlorophenyl hydrazone; DFP: deferiprone; ER: endoplasmic reticulum; FKBP8: FKBP prolyl isomerase 8; GABARAPL: GABA type A receptor associated protein like; LC: liquid chromatography; LOD: limit of detection; LOQ: limit of quantification; MAP1LC3: microtubule associated protein 1 light chain 3; MS: mass spectrometry; NCOA4: nuclear receptor coactivator 4; NBR1: NBR1 autophagy cargo receptor; NUFIP1: nuclear FMR1 interacting protein 1; OPTN: optineurin; PHB2: prohibitin 2; PNPLA2/ATGL: patatin like phospholipase domain containing 2; POI: protein of interest; PTM: posttranslational modification; PRM: parallel reaction monitoring; RB1CC1/FIP200: RB1 inducible coiled-coil 1; RETREG1/FAM134B: reticulophagy regulator 1; RPS6KB1: ribosomal protein S6 kinase B1; RTN3: reticulon 3; SARs: selective autophagy receptors; SQSTM1/p62: sequestosome 1; STBD1: starch binding domain 1; TAX1BP1: Tax1 binding protein 1; TFEB: transcription factor EB; TNIP1: TNFAIP3 interacting protein 1; TOLLIP: toll interacting protein; ULK1: unc-51 like autophagy activating kinase 1; WBP2: WW domain binding protein 2; WDFY3/Alfy: WD repeat and FYVE domain containing 3; WIPI2: WD repeat domain, phosphoinositide interacting 2.

cell biology

Developing potent LC3-targeting AUTAC tools for protein degradation with selective autophagy

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Inhibition of Autophagy by a Small Molecule Through Covalent Modification of the LC3 Protein

Autophagy mediated targeting degradation, a promising strategy in drug development

The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system

Manipulating Autophagic Degradation in Human Diseases: from Mechanisms to Interventions

Emerging degrader technologies engaging lysosomal pathways

Perspectives of Autophagy-Tethering Compounds (attecs) in Drug Discovery

Drug discovery by targeting the protein‒protein interactions involved in autophagy

Targeting Lysosomal Degradation Pathways: New Strategies and Techniques for Drug Discovery

Targeting Lipid Droplets for Autophagic Degradation by ATTEC

Discovery of small molecules for autophagy-lysosome degradation of immune checkpoint proteins

Degradation of Lipid Droplets by Chimeric Autophagy-Tethering Compounds

Targeting autophagy in disease: established and new strategies

Tethering ATG16L1 or LC3 induces targeted autophagic degradation of protein aggregates and mitochondria

Advancing targeted protein degradation for metabolic diseases therapy

Identification and Functional Studies of New Autoph-agy Protein Machinary

Structure-Based Design and Discovery of a Potent and Cell-Active LC3A/B Covalent Inhibitor.

Targeting autophagy drug discovery: Targets, indications and development trends

Targeting the Undruggables ---- the Power of Protein Degraders

Targeted proteomics addresses selectivity and complexity of protein degradation by autophagy